相关实验视频

Updated: May 9, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

比较贝波塔斯和迪芬胺对瑞图西马布诱导的输液反应的抑制作用

Tomoki Hori^1,2, Kazuhiro Yamamoto^3,4, Tomoaki Nakagawa¹

¹Department of Pharmacy, Nara Prefecture General Medical Center, 2-897-5 Shichijo-Nishimachi, Nara, 630-8581, Japan.

International journal of hematology

|April 29, 2025

概括

贝波塔斯显著降低了与丁芬胺相比,与修复剂诱导的输液相关反应 (IRR) 的发生率. 这表明贝波塔斯是预防这些常见不良事件的更有效选择.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

输液相关反应 (IRR) 是与rituximab治疗相关的常见不良事件.
第一代组胺1受体对抗剂 (H1RAs) 通常用于IRR预防.
关于第二代H1RAs (如贝波塔斯) 对Rituximab诱导的IRR有效性的数据有限.

研究的目的:

为了评估贝波塔斯对利图西马布诱导的IRR的抑制作用.
为了比较贝波塔斯与第一个代H1RA的迪芬胺在预防Rituximab诱导的IRR方面的疗效.

主要方法:

追溯评估B细胞非霍奇金淋巴瘤患者的IRR发病率,这些患者接受了第一剂rituximab.
贝波塔斯前期治疗的患者和用迪芬胺治疗的患者之间的IRR率的比较.

主要成果:

任何级别的IRR的发生率在贝波塔斯组 (9.8%) 与迪芬胺组 (30.2%;p < 0.001) 相比显著较低.
2级或更高IRR的发生率在两组之间是相似的 (6.5%对12.5%;p = 0.16).
贝波塔斯前期治疗是降低任何等级IRR风险的一个独立因素 (OR = 0.19).

结论:

贝波塔斯在减少瑞图西马布诱导的IRR的总体发病率方面表现出比迪芬胺更高的疗效.
贝波塔斯在预防低度输液相关反应方面可能特别有效.
需要进一步的前性研究来证实这些发现.

关键词:

贝波塔斯提因 (Bepotastine) 是一种药物.这是一种二胺胺.输注反应是输注反应.里图西马布 (Rituximab) 是一种药物.

更多相关视频

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...

Parenteral Anesthetics: Overview

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.